Vertex receives chmp positive opinion for kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat people with cystic fibrosis with at least one f508del mutation

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) adopted a positive opinion for the label extension of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (cf) in all patients ages 12 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conduct
VRTX Ratings Summary
VRTX Quant Ranking